Searchicon: search

Nobivac® NXT Canine Flu H3N2

icon: canine

Product Description


Nobivac® NXT Canine Flu H3N2 is the only CIV vaccine with a labeled 1-year duration of immunity.1

product Label

Overview

Technical

Features & Benefits


Modernized

  • Targets H3N2, the only circulating canine strain2,3

Smaller dose

  • A low-volume 0.5 mL dose provides a more gentle vaccine experience.

No extraneous material

  • Nobivac® NXT-level protection in a preservative-free, adjuvant-free, thimerosal-free formulation.

How It Works

Discover the science behind Nobivac® NXT-level RNA particle technology. See how this revolutionary new way of delivering protection provides an exciting new option for you and your patients.

Downloads

icon: download

Nobivac NXT Canine Flu H3N2 Detailer

Protect against today’s canine influenza virus threat with a smart, streamlined vaccine

icon: arrow-rightDownload
icon: download

Your guide to the prevention and management of canine influenza virus

Addressing Canine Influenza

Use this brochure to help guide your practice in the identification, containment, and prevention of CIV outbreaks.

icon: arrow-rightDownload

Product Specifications

Administration

  • For primary immunization, administer 1 dose (0.5 mL) subcutaneously as early as 8 weeks of age followed by a second dose 3 to 4 weeks later

Indication

  • This product has been shown to be effective for the vaccination of healthy dogs 8 weeks of age or older against canine influenza virus H3N2. The duration of immunity is at least 1 year.

Supplied

  • 25 doses per tray

Safety

  • Safety has been demonstrated in dogs 8 weeks of age and older

Uncompromising Safety and Efficacy

SIGNIFICANTLY REDUCES COUGHING AND LUNG LESION SCORES (P<0.0001)

icon: plus icon: minus

*The standardized method of evaluating efficacy of canine influenza vaccines is based on lung lobe consolidation.6

† Two doses of Nobivac® NXT Canine Flu H3N2 were administered to 8-week-old puppies, subcutaneously, 3 weeks apart. Challenge was conducted 2 weeks post 2nd vaccination. Clinical observations were recorded for 10 days post-challenge, and nasal swabs were collected for 10 consecutive days to determine viral shedding. Lungs were evaluated 10 days following challenge.

‡ P<0.0001

SIGNIFICANTLY REDUCES THE DURATION OF VIRAL SHEDDING.

icon: plus icon: minus

§Two doses of Nobivac® NXT Canine Flu H3N2 were administered to 8-week-old puppies, subcutaneously, 3 weeks apart. Challenge was conducted 2 weeks post 2nd vaccination. Clinical observations were recorded for 10 days post-challenge, and nasal swabs were collected for 10 consecutive days to determine viral shedding. Lungs were evaluated 10 days following challenge.

|| Magnitude of viral shedding on Day 1 – P=0.0001

¶ Overall duration of viral shedding and magnitude of viral shedding – P<0.0001

PROVEN SAFE ACROSS A VARIETY OF BREEDS AND AGES.

icon: plus icon: minus

A field safety study proved Nobivac® NXT Canine Flu H3N2 to be well tolerated in a wide range of canine patients7

  • 1,301 doses administered to 654 dogs of various breeds
  • Dogs ranged in age from 8 weeks to 15 years
  • Lethargy was the most common adverse event (1.6%)

Disease Information

CANINE INFLUENZA VIRUS

icon: plus icon: minus

Canine influenza virus (CIV) causes a respiratory infection in dogs that is also known as dog flu. The infection is very contagious to other dogs. Laboratory surveillance indicates the H3N2 strain of CIV as the critical strain of concern.2,3

Transmission/Clinical signs

icon: plus icon: minus

Transmission

  • Direct contact (licking, nuzzling)
  • Indirect (coughing or sneezing)
  • Contaminated surfaces such as food and water bowls, cages
  • Human contact

Clinical Signs

  • Coughing (dry or moist)
  • Sneezing
  • Fever
  • Nasal discharge
  • Lack of energy
  • Loss of appetite

Risk factors

icon: plus icon: minus

Risk Factors

  • Dogs that come from shelters, rescue centers, breeding kennels, or pet stores
  • Boarding at a kennel or doggie daycare
  • Visiting groomers, dog parks, or engaging with other dogs
  • Dogs that participate in events/competitions
  • Dogs that travel
  • Dogs of veterinary staff that may be exposed through contaminated fomites
  • Sharing an elevator or other confined space with other dogs

NOBIVAC® NXT-GENERATION PROTECTION

Learn more about Nobivac® NXT technology, the latest vaccine platform from Nobivac®.

LEARN MORE

References

  1. Nobivac® NXT Canine Flu Product label. Merck Animal Health.
  2. Results from samples submitted for CIRD testing in the US. IDEXX Laboratories.
  3. Sykes J. Infectious Diseases of the Dog and Cat, 5th ed. Elsevier; 2023:313-316.
  4. Centers for Disease Control and Prevention. About Equine Influenza (Horse Flu). CDC. Updated May 16, 2024. Accessed December 3, 2025.
    https://www.cdc.gov/flu-in-animals/about/horse-flu.html
  5. Wasik BR, Rothschild ER, Voorhees IEH, et al. Understanding the divergent evolution and epidemiology of H3N8 influenza viruses in dogs and horses. Virus Evol. 2023;9(2):1-14. doi:10.1093/ve/vead052.
  6. Deshpande MS, Jirjis FF, Tubbs AL, et al. Evaluation of the efficacy of a canine influenza virus H3N8 vaccine in dogs following experimental challenge. Vet Therapeut. 2009;10(3): 103-112.
  7. Data on file. Merck Animal Health.